GlassScriptPhysician profile
Rex N Gentry
NPI 1316157258
$690.78
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $599 · 2020: $92.24.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $180.52 | 2019-2020 | |
| Allergan, INC. | $165.10 | 2019 | |
| Janssen Pharmaceuticals, INC | $106.45 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $77.42 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $58.96 | 2019 | |
| Bausch Health US, LLC | $41.99 | 2019-2020 | |
| Lundbeck LLC | $24.22 | 2020 | |
| Vanda Pharmaceuticals INC. | $20.94 | 2019 | |
| Merck Sharp & Dohme LLC | $15.18 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rex Gentry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.